| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1877856 | Applied Radiation and Isotopes | 2011 | 7 Pages |
Abstract
SummaryThe CGS 25966 derivative (R)-2-(N-Benzyl-4-(2-[18F]fluoroethoxy)phenyl-sulphonamido)-N-hydroxy-3-methylbutanamide [18F]9 represents a very potent radiolabelled matrix metalloproteinase inhibitor. For first human PET studies it is mandatory to have a fully automated radiosynthesis and a straightforward precursor synthesis available. The realisation of both requirements is reported herein. In particular, the corresponding precursor 8 was obtained in a reliable 7 step synthesis with an overall chemical yield of 2.3%. Furthermore, the target compound [18F]9 was prepared with a radiochemical yield of 14.8±3.9% (not corrected for decay).
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Stefan Wagner, Andreas Faust, Hans-Jörg Breyholz, Otmar Schober, Michael Schäfers, Klaus Kopka,
![First Page Preview: The MMP inhibitor (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis The MMP inhibitor (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis](/preview/png/1877856.png)